Omar M. Khateeb

State of MedTech

Media company that produces a live show, webinars, podcast, and newsletter with over 6k medtech professionals, investors, and healthcare providers. The majority of our content is eligible for CME via provider's reflection. We work with medtech, biotech, and other healthcare companies looking to reach physicians in new and engaging ways.

Podcast Host 

OmniCreator

OmniCreator is an invitation-only community for LinkedIn creators. The members expand their network and audience through the OmniCreator SaaS app. Want to join? Head to OmniCreator.Club

Co-Founder

Khateeb & Co.

Helping medtech companies grow sales and drive product adoption through social media and content.

Founder

Medical Sales Network Effects Program

The only medical sales course that teaches you how to drive product adoption and grow pipeline using digital channels such as LinkedIn, Email, Video Sales Letters and more.

Course Instructor

Gentem Health

Gentem is a Fintech SaaS company that helps private practices thrive by simplifying revenue cycle management with an end-to-end billing platform that helps providers get paid on time and in full so they can focus more on treating patients.

While at Gentem I launched their website and laid the foundation for their initial growth strategies as well as brand identity.

Head of Growth

Potrero Medical

This was the company where my career in growth took flight. Alongside CEO Joe Urban, we designed a category to launch and dominate (Predictive Health). While at Potrero, we were very heavy on media and using growth strategies to grow awareness with the market and investors. We were also the first medical device company with a podcast. 

One of my accomplishments was during the start of the pandemic I was allowed to put my growth strategies to the test by generating surgeon interest in open geographies. Within 60 days I had put on 35 demos that created the most deals in the company. I did not close these deals but my thesis around using social media to grow awareness, generate demand, and demo virtually was validated. 

When I left Potrero the deals I had put in the pipeline ranged from the most prestigious academic centers to large for-profit IDNs as well as regional hospitals. The departments also ranged from cardiac surgery to critical care.

Director of Growth Marketing

ps mister

ps mister is a fashion inventions company that developed a product for holding and folding pocket squares. We overfunded on our Kickstarter crowdfund (178%), ranked in the top 5 products for pocket squares, and delivered our product ahead of time to all customers.

- Funded over 178% over funding goal
- Ranked 3rd in magic category for all pocket square products on Kickstarter
- 3rd most popular pocket square product on Kickstarter
- 6th most funded pocket square product on Kickstarter
- 6th most backed pocket square product on Kickstarter

I currently serve as an advisor as the company is being led by my co-founder Adam Ben-Evi

Restoration Robotics

I was responsible for running DTC campaigns to develop regional markets, capture leads, and help practices increase utilization of the technology.


• Helped market development team drive $3M in revenue from Facebook lead generation program
• Increased capital sales webcast attendance by 91% and captured 467 physician leads
• Trained customers on business development and digital patient acquisition strategies
• Introduced digital tools for capital sales and practice development teams to use in evaluating
markets and influencing technology adoption
• Helped grow brand footprint by leveraging corporate-branded assets into local markets through
various digital and social media channels

Marketing Manager, Procedure Growth & Utilization

My role focused on contributing to product strategy, procedure marketing to physicians and patients, and managing marketing programs to introduce new product and service offerings to the targeted global markets. This also includes managing social media strategies such as Facebook lead generation, direct-to-consumer campaigns, and webcasting to drive adoption and utilization.

• Helped market development team drive $3M in revenue from Facebook lead generation program
• Increased capital sales webcast attendance by 91% and captured 467 physician leads
• Trained customers on business development and digital patient acquisition strategies
• Introduced digital tools for capital sales and practice development teams to use in evaluating
markets and influencing technology adoption
• Helped grow brand footprint by leveraging corporate branded assets into local markets through
various digital and social media channels

Marketing Manager, Product and Platform Technologies

MedTech Momentum

The company aimed at developing and managing marketing strategies for medical device companies. 

I was responsible for developing, coordinating and driving successful execution of strategic marketing plans for our customers. The majority of our strategy is digital marketing.

This included all upstream and downstream marketing activities to drive our customer's revenue and increase their market share.

Strategic Director

Mazor Robotics (Acquired by Medtronic for $1.6B)

Mazor Robotics was a  medical device company and the world's first robotic guidance system for spine and later developed neurosurgery application with. The company was acquired by Medtronic for $1.3B. Some of my career highlights were:

-Executed commercial launch of PROlat™ procedure in March 2016. The procedure was a cutting edge development in lateral spine surgery as well as minimally invasive spine surgery.

-Launched first major live surgery event in company history.

-Developed and managed business development and sales processes that affected clinical and capital sales team which was made up of 45 sales representatives, 7 clinical sales managers, and 10 capital sales managers. 

-Managed a marketing/sales budget of $2M. 

-Streamlined divisions by developing a corporate marketing plan.

-Improved operating efficiencies through negotiating contracts and leveraging internal assets. 

-Redesigned lead generation strategy. 

-Designed effective trade show booth strategy. 

-Increased activity of marketing programs by focusing on marketing-to-sales differentials in underachieving markets.

US Marketing Manager

-Managed accounts in El Paso and San Antonio, TX. 

-Hit above quota 3 of 4 quarters.

-Held quarterly business development meetings with hospital executive teams to review marketing strategies. 

-Developed sales and clinical training documents.

-Provided clinical support for the state of Texas as well as other US accounts.   

-Trained surgeons and staff on the Renaissance Robotic Guidance System and complementary products in order to provide a more accurate, reproducible surgery as well as a safer surgical environment for patients, surgeons and OR staff. 

-Consulted surgeons prior to surgery on surgical planning and execution of spinal surgery.

-Provided clinical support and training in minimally invasive and percutaneous surgical approaches. 

-Collaborated with US sales team in creative manner to improve on existing programs and sell active Renaissance surgeons on the concept of developing procedure and advanced training programs.

-Collaborated with hospitals on strategic marketing in order to grow robotic programs.

-Cultivated surgeon's expertise on software based pre-operative clinical planning as well as execution of minimally invasive robotic spine surgery.

Clinical Sales Representative

Helping Medtech Startups Get Investors & Grow Commercial Pipeline Using Social Media |🎙️ Host of MedTech's #1 Podcast | Proud Husband & Father | Avid Reader | Jiu Jitsu @Carlson Gracie | Mentor | Coach

My story might be a shock but my mission is simple: I want to change how medtech companies sell and market to physicians by using social media in a powerful new way.

Here's my story:

Growing up in the US/Mexico border town of El Paso, Texas I am a first generation American. 

The idea of discipline, honor, and hard work were engrained in me by my parents.

I went to medical school on an academic scholarship and dropped out in 2012 to pursue a career in technology.

I found my way into an exciting surgical robotics company called Mazor Robotics, the first robotic spine company. 

I started off "carrying the bag" as a clinical sales rep before quickly getting promoted to US Marketing Manager for my ability to do great patient marketing campaigns and market the technology.

The past decade has been spent at various high-tech startups driving growth and technology adoption through growth marketing and category design. 

This includes two publicly traded surgical robotic companies through their IPOs as well as co-founding a consumer product for men’s fashion.  

In 2022 I launched my own venture, Khateeb & Co, with a mission to  help medical sales people drive technology adoption using social media. 

I also launched a media company called "The State of MedTech" which helps physicians and industry professionals learn more about the latest trends in medicine through a podcast, webinar, blog, and live show. The majority of the episodes offer CME credits via a physician's reflection. 

My areas of focus are category design, driving adoption of new technologies, and developing strategies to channel attention towards generating demand.

In my spare time, I love teaching and mentoring young professionals. Im an avid reader and also paid public speaker.

You can follow me on Facebook, Instagram, Twitter (@OmarMKhateeb) or Youtube (Mind Loom with Omar M Khateeb).

Podcast Host

Nothing is more powerful than an idea whose time has come. This podcast is about those ideas. Interviews with authors, speakers, and rebels on the most thought-provoking ideas.

One thing about #MTC25 was seeing so many State of Medtech alumni. Here’s who I saw and their podcast episode # so you can listen  👇

309. Amaan Mazhar CEO of Modulim
298. Adrian Mendes CEO of Perimeter Medical Imaging AI
293. Craig Gaffin President of Global Orthopaedics at Smith+Nephew
287. Laura Francis CEO of SI-BONE 
270. Todd Usen CEO of Adagio Medical Inc.
260. Lishan Aklog, MD CEO of Lucid Diagnostics
250. Cardiology Investor Ken Nelson  
163. IntelVasc Inc CEO Andrew Ortega-Verdaguer
90. Lisa Carmel Chair of Business Development at Mayo Clinic

#medtech #medicaldevices #medicaldevice The MedTech Conference

Helping Medtech CEOs Attract Investors & Grow Sales Using Social Media| Marketing Agency Owner |🎙️ Host of MedTech's #1 Podcast | Proud Husband & Father | Avid Reader | Jiu Jitsu @Carlson Gracie | Mentor | Coach

This is a wild healthcare story- In the 90s the 𝐅𝐞𝐫𝐫𝐚𝐫𝐢 𝐩𝐢𝐭 𝐜𝐫𝐞𝐰 𝐭𝐞𝐚𝐦 𝐡𝐞𝐥𝐩𝐞𝐝 𝐚 𝐔𝐊 𝐂𝐡𝐢𝐥𝐝𝐫𝐞𝐧'𝐬 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥 improve its ICU hand-off process.

In London’s Great Ormond Street Hospital, doctors once looked to Ferrari. Why? Because handoffs from the operating theatre to ICU are high-stakes — just like an F1 pit stop.

By inviting Ferrari’s precision mindset into medicine, they:
-Defined 1–2 tasks per person
-Introduced a “lollipop man” role to signal the go
-Simulated workflows, rigged checklists, and phased handover stages
- Separated technical setup from informational exchanges

The result? 
The incident rate of combined equipment + information errors fell from ~30% to ~10%.

What does this teach us?

 When systems are complex, error isn’t just about individuals, it’s about design. 

Look outside your field. Steal the ideas. Make them your own.

Helping Medtech CEOs Attract Investors & Grow Sales Using Social Media| Marketing Agency Owner |🎙️ Host of MedTech’s #1 Podcast | Proud Husband & Father | Avid Reader | Jiu Jitsu @Carlson Gracie | Mentor | Coach

So everyone is seeing the news now about J&J's Orthopaedics Spin-Off. But this is more than just a restructure.

With the announcement that Johnson & Johnson will spin off its ortho unit, DePuy Synthes, we’re seeing another strategic signal in the ongoing reshaping of big medtech.

📉 As the chart below shows, orthopaedics has steadily declined as a share of J&J’s MedTech revenue - down from 32% in 2021 to 29% in 2024 - while cardiovascular and surgical categories are scaling fast.

🔍 Why this matters:
 This move isn't just about "unlocking value" - it reflects the accelerating shift toward higher-growth, higher-margin verticals. 

J&J is doubling down on areas like cardiovascular, oncology, and surgery - where innovation is faster, margins are wider, and competitive moats are deeper.

🦴 Meanwhile, DePuy Synthes will stand alone as a $9.2B orthopaedics pure-play - potentially leaner, more agile, and better positioned to refocus on MSK innovation.

📊 For investors, startups, and strategics:
I expect further portfolio focus plays across large-cap medtech.

That means M&A and partnerships where orthopaedics leaders may seek tech-enabled differentiation.

And pay attention to where growth capital is flowing, this rebalancing is far from over.

I think this is a great thing because now there are more players entering the market (call them mini strategics) who can now be more aggressive in M&A since theyre no longer tied to a gigantic Fortune 100.

For strategics the takeaway is that scale alone is no longer the strategy. 

Focused scale is.

*Be sure to check out our monthly "This Month in Medtech" series on State of Medtech in partnership with the amazing and trusted market intel team at LSI

#orthopaedics #medicaldevice #medicaldevices #medtech #orthopedics

Next time you wanna quit look at this photo of Elon right after a failed SpaceX launch. 

This is from SpaceX's first Falcon 1 launch failure on March 24, 2006. 

The rocket crashed 41 seconds after liftoff due to a fuel line leak and fire. It was the first of three early failures before successes in 2008-2009.

How INBRAIN Neuroelectronics Could Rewire the Brain using Graphene with CEO Carolina Aguilar.

#Medtech #AI #BCI #Neurotech #Parkinsons

For medech execs at the director level and above, this event is capped at only 200 people and worth applying for. Here's why you need to get in 👇

We all know that the future of MedTech is accelerating, and staying at the forefront means being in the room where innovation is born and strategic partnerships are forged.

This is the room you have to be in.

MedTech USA 2025 is happening in a couple weeks, Nov 3-4, in Boston.

This isn't just another event – it's the essential gathering for leaders shaping the next wave of healthcare technology.

From the rapid adoption of AI to elevating patient-centric design, this is your unparalleled opportunity to dive deep into critical conversations and make a tangible impact.

The team over at Reuters Events meticulously designed the experience to maximize your networking potential and ensure every interaction counts. 

Their robust networking features include:

Networking Concierge Support: Get personalized matches with attendees whose goals align with yours.
 
Relationship Building Sessions: Break the ice and spark meaningful discussions with themed conversation starters.
 
Curated Networking Zones: Foster spontaneous dialogue and peer-to-peer learning in dedicated spaces.
 
Available with upgrade: The Hosted Buyer Program: Meet pre-qualified vendors tailored to your needs, streamlining your search and saving you months of research.

This isn't just about attending; it's about building relationships, discovering solutions, and propelling your organization forward. 

Apply to get your Guest Pass now: 
https://bit.ly/3W61MCp

#medicaldevices #medicaldevice #medtech 
#REMedTech #HealthcareInnovation #Networking #AIinHealthcare #PatientCentric

There’s something everyone missed from the keynote with Arnold Schwarzenegger and Ivan Tornos  

Scott Whitaker  did a fantastic job moderating the interview and pulling some amazing stories from Arnold while Ivan gave a great talk on how the partnership happened. 

If I had to summarize my biggest takeaway from Arnold’s philosophy and health and Ivan’s vision at Zimmer….

Just keep moving. But that’s just the surface level of the real takeaway. 

Not just physically, but energetically.

Arnold’s philosophy of relentless motion isn’t just about muscles or momentum but about consciousness in motion. 

In metaphysical terms, movement collapses potential space into lived reality. 

You start moving with life instead of against it.

“Go with the flow”

Ivan’s vision mirrors this in that innovation as a living frequency, not a static strategy. 

Every step forward tunes the organization into a new vibrational state of possibility.

Why do you think he’s consistently posting online and across channels? It’s not just for fun. 

Neville Goddard once said, “Leave the mirror and change your face.”

Movement - inner or outer - is how we change the face of reality. 

Each action, thought, or assumption sends a signal through the field, saying:

“I am alive. I am evolving. I am creating.”

Progress isn’t linear but recursive, every forward motion loops back, revealing deeper harmony in the system.

In Arnold’s language, it’s simpler: “Just keep going.”

Both point to the same truth:
Keep moving — and reality moves with you.

#mtc25 The MedTech Conference

Something that I think many missed ( somehow I didn’t and I’m pretty plugged in). Medline Industries, LP  is set to launch its IPO late this year, aiming to raise $5B at a $50B valuation – potentially the biggest medtech IPO of the year and possibly a top 5 ipo in history for Medtech. 

Filing this month (Oct 2025), with a listing by November. 

Here’s what this means.
Medline, a global leader in medical supplies, went private in 1977 when the Mills brothers bought it back. 

In 2021, PE firms Blackstone, Carlyle, Hellman & Friedman, and GIC acquired it. Now, with $25.5B in 2024 net sales, they’re returning to public markets. 

Why the IPO? 
1️⃣ Growth Capital: Funds to expand globally, leveraging a $23B+ revenue base. 

2️⃣ Debt Relief: Pay down leverage from the 2021 buyout. 

3️⃣ Market Timing: Aging populations drive healthcare demand – perfect for a $50B play. 

Per IPOX data, Medline’s revenue soared from $10B in 2019 to $25.5B in 2024, ranking it 2nd among medical device firms. 

This growth outpaces peers like Stryker ($150.74B market cap) and Medtronic ($111.36B), signaling strong fundamentals. 
Key insights:

🔥ESG Risks: Past safety issues (e.g., $15M bed recall) and $85M kickback settlement linger, but innovations like Microsoft AI partnerships show adaptability.

🗡️Competitive Edge: Outranks industry giants in revenue growth, despite historical legal hurdles. 

For investors, this IPO signals medtech’s resilience. 

With a P/E ratio lower than peers (e.g., Baxter at 18.7x vs. industry avg), it’s a value play in a $10T healthcare market by 2026. 

Watch for the S-1 filing led by Goldman Sachs and Morgan Stanley.

📈Bottom line: Medline’s IPO could redefine medtech investing, blending PE exit strategy with healthcare’s growth story. Bullish or cautious?

Innovations in Coronary Imaging: A Conversation with Eman Namati CEO at SpectraWAVE, Inc.

#MedTech #Cardiology #AIImaging #IntravascularImaging #SpectraWave

Redefining Rotator Cuff Surgery with Oke A. Anakwenze MD, MBA CEO & Founder  of SutureTech
#MedTech #Orthopedics #Surgery #Innovation #HealthcareTech

Mitra Soltani great graphic. This all points to one direction: ecosystems.
What this predicts is...

-OR/cath-lab ecosystems: bundled capital + disposables + AI guidance + services.
-Closed-loop chronic care: sense–decide–act across diabetes, rhythm, heart failure.
-Software-led margins: subscriptions, fleet analytics, outcome-based pricing.
-Data moats: longitudinal imaging/physiology data becomes the defensible edge.

The implication is to integrate suites and lock workflows while building plug-ins that prove cost-out and outcome lift.

Driving Reliability for MedTech & Defense through Zero-Failure Innovation | Visionary Systems Leader

Q2 2025 MedTech Market Snapshot

Medtronic leads the pack with $33.12B, powered by innovations like the Micra™ leadless pacemaker, MiniMed™ 780G insulin pump, and Intellis™ neurostimulator.

Johnson & Johnson follows closely at $31.85B, driven by Vistaseal™, Acclarent™, and Biosense Webster™ technologies.

Stryker holds strong with $22.59B, thanks to the Mako™ surgical robot, Neptune™ waste system, and advanced spine implants.

Other standout performers:

• Abbott: $18.98B — FreeStyle Libre™, HeartMate 3™, Confirm Rx™
• Boston Scientific: $16.74B — Watchman™, Emblem™, LithoVue™
• BD: $15.40B — Alaris™, Pyxis™, BD MAX™
• GE HealthCare: $13.07B — Revolution CT™, LOGIQ™, Vivid™
• Cardinal Health: $12.49B — Kangaroo™, Curity™, Monoject™
• Intuitive: $8.35B — da Vinci™ Surgical System
• Olympus Corporation: $6.96B — EVIS X1™, Thunderbeat™, Visera™


This chart isn’t just about revenue — it’s a reflection of clinical impact, technological leadership and market momentum across surgical robotics, diagnostics and patient monitoring.

------
Follow Mitra Soltani for more insights on how MedTech can grow smarter, not just bigger.

Infographic titled "Top Selling Medical Devices of MedTech Giants Based on Q2 Revenue 2025."

Medtronic: $33.12B

Stryker: $22.59B

Johnson & Johnson: $21.85B

Boston Scientific: $16.74B

GE HealthCare: $13.07B

Cardinal Health: $12.49B
Each company logo is shown alongside product images and revenue figures.

At #MTC2025 until Wednesday! Excited to catch up with peers, strategies and investors. If you see me come say hi.

"There's too much capital in VC". Sunday's I lift in my garage while learning from outside of medtech. Today was Sequoia Capital's Roelof Botha from All-In Podcast summit. My takeaways and what they mean for medtech 👇

1. Too Much Money, Not Enough Discipline
Botha was blunt: there’s too much money in venture.

 He called it “return-free risk”. Capital is flooding in faster than true innovation, creating the illusion of progress.

Even in the best decades, only about 20 companies/year reach billion-dollar outcomes. More money doesn’t mean more innovation..just more noise.

 And when rules are unclear, founders stop building: China saw a 98% drop in new startups from 2018–2023 due to regulatory uncertainty.

👉 Medtech takeaway: Predictable regulation is oxygen for innovation. Without clarity and trust, even breakthrough medical ideas can’t take root.

2. Sequoia’s Edge: Patience and Compounding

Sequoia keeps its funds small by choice , unchanged in size for nearly a decade. 

Their goal: be the best performers, not the biggest fee generators.

Its a reminder that the biggest value often comes after IPO. Look at some of the IPOs in medtech (Heartflow, Ceribell, Kestra, Medline soon)

 That’s why Sequoia launched the Sequoia Capital Fund, allowing them to hold long-term compounders like Nvidia and Google. 

That patience has already generated $6.7B in additional gains for investors.

👉 Medtech takeaway: True value in healthcare compounds over time. Through data, validation, and trust. The best results come after the “exit milestones,” not before them.

3. Founders Who Change the World Think Differently

Sequoia backs “exceptional people who aren’t always easy to get along with.”
 
World-changing founders challenge norms, refuse “no,” and keep reinventing. 

Botha calls it having multiple founding moments  e.g. when Square launched Cash App years after its start.

👉 Medtech takeaway: The best Medtech founders do the same. They evolve from device to data, from hardware to platform, reinventing their model to drive lasting impact.

4. Culture, Curiosity, and Precision

At Sequoia, culture is strategic.

Partners are expected to be curious, driven, and kind-hearted  and every investment requires consensus, meaning one “no” can stop a deal. That keeps standards high.

Behind the scenes, Sequoia has as many developers as investors, building AI tools that assess markets, competition, and product quality. Operational excellence is the unseen advantage.

👉 Medtech takeaway: The future of healthcare innovation belongs to teams who blend empathy with data mastery — human insight guided by intelligent systems.

Closing Thought
My key unlock from this is that discipline, patience, and conviction win.

Focus and restraint are the ultimate edge.

In Medtech progress happens over years, not quarters, so that mindset isn’t optional. It’s the difference between those who win bigly and the rest.

#medtech #medicaldevices #digitalhealth #venturecapital

It was big news for me when I heard Virtual Incision landing Jim Alecxih as the new CEO. Here’s our episode with him on why after a decade post intuitive made him join Virtual Incision and the market opportunity ahead for them. 

 #Medtech #SurgicalRobotics #Healthcare #AI #Entrepreneurship  #medicaldevices

Chris Kosrow  from Showpad and I dove into how  you can use AI to Revolutionize MedTech Sales

#MedTech #DigitalHealth #SalesEnablement #AIinSales #Showpad

Sunday morning reading. Few reasons why Medtech investors and founders need to read this.👇 


*First Stripe  has a press/publication arm that I’m convinced has the greatest book UX website ever along with amazing books.

So let’s dive in. 

Most people think bubbles = bad for business.

But what if bubbles are exactly what your Medtech startup needs?

Im reading this not for fun, but to help our medtech marketing partners at MarketCraft  fundraise and commercialize in radically more effective ways.

The authors argue something bold:
👉 That financial bubbles — yes, the ones people fear — are actually engines of massive innovation.

From the Apollo program to Bitcoin, they show how breakthroughs weren’t born from cautious planning…

They were born from belief-driven over-investment, shared vision, and a willingness to take on massive risk.

Here’s why this matters for MedTech:

🧠 Most startups pitch incremental progress.
But what if your device is part of a movement, a “bubble” that changes medicine itself?

📈 What if you didn’t just sell precision…
But positioned your tech as a key domino in the next era of surgical robotics or AI-driven diagnostics?

That’s what we help our partners do -not just launch products, but craft compelling fundraising narratives that attract visionary investors, and create markets before they’re ready.

📚 This book reframes risk as the fuel of transformation.

And if we want to break out of the “Great Stagnation” in MedTech, the time is now.

Because no one gets excited about technology with incremental clinical benefit.

They get excited about redefining how medicine works.

Only a few days away and a few guest spots are open! Apply and if accepted you attend as VIP) MedTech USA 2025 (Nov 3-4, Boston) isn't just another event – it's the essential gathering for leaders shaping the next wave of healthcare technology. 

From the rapid adoption of AI to elevating patient-centric design, this is your unparalleled opportunity to dive deep into critical conversations and make a tangible impact.

The Reuters team has meticulously designed the experience to maximize your networking potential and ensure every interaction counts. 

Quick glance of the amazing networking features:

 Networking Concierge Support: Get personalized matches with attendees whose goals align with yours.

 Relationship Building Sessions: Break the ice and spark meaningful discussions with themed conversation starters.

 Curated Networking Zones: Foster spontaneous dialogue and peer-to-peer learning in dedicated spaces.

 Available with upgrade: The Hosted Buyer Program: Meet pre-qualified vendors tailored to your needs, streamlining your search and saving you months of research.

It's an amazing list of people getting together so you dont want to miss this.
Apply for your guest pass here:
https://bit.ly/3W61MCp

#REMedTech #HealthcareInnovation #MedicalDevices #Networking #AIinHealthcare #PatientCentric #medicaldevice medtech

"I thought of my father, crying at the kitchen table because his boss humiliated him. I decided then: dignified work, or no work at all."

Brunello Cucinelli built a $7B cashmere empire on that principle. And it's profitable.

His daily routine is something I always have in mind as we grow MarketCraft  

Granted, my days cant completely be like that between the business, children etc but I always look at my calendar and make sure that its not just a day full of zoom calls.

October's edition of "This Month in Medtech" on State of Medtech releases today in partnership with LSI and we got some really big topics to cover. Quick teaser 👇

Boston Scientific doubled down on neuromod with a $533M buyout, 
J&J spun off its $9.2B orthopedics unit, and investors shifted toward fewer, bigger, later-stage bets. 

Add in Stryker + Siemens teaming up on stroke robotics, and you’ve got one of the most pivotal months of the year.

We break it all down — plus reveal the Q4 Hot 25 startups to watch heading into 2026.
 
#medtech #techmed #digitalhealth #medicaldevices #medicaldevice Nicholas Talamantes

Our new episode of This Month in Medtech is live with October’s biggest moves.
• Boston Scientific doubles down on neuromod (Nalu buy)
 • J&J spins out orthopedics robotics race heats up
 • Q3 funding: fewer deals, bigger bets (+larger round sizes)
 • Stryker x Siemens team on stroke robotics
 • Plus: LSI’s Q4 Hot 25 you need to watch
#Medtech #HealthcareInnovation #MedicalDevices #VentureCapital #DigitalHealth

taplio

Omar M. Khateeb's Linkedin Analytics

Omar M. Khateeb

Performance ScoreOmar M. Khateeb's LinkedIn Performance

What is Omar M. talking about?

Omar M. Khateeb's Best Posts (last 30 days)

Ready to grow your LinkedIn presence?

taplio

.css-6ytdur{background-image:linear-gradient(284deg, rgba(39, 43, 72, 1) 0%, rgba(33, 47, 183, 1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Omar M. Khateeb's Linkedin Analytics

Omar M. Khateeb

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}Omar M. Khateeb's LinkedIn Performance

What is Omar M. talking about?

Omar M. Khateeb's Best Posts .css-1emoo84{font-size:var(--chakra-fontSizes-md);font-weight:400;color:var(--chakra-colors-gray-600);}(last 30 days)

Ready to grow your LinkedIn presence?

Omar M. Khateeb's Linkedin Analytics

Performance ScoreOmar M. Khateeb's LinkedIn Performance

Omar M. Khateeb's Best Posts (last 30 days)